A Study of LY3361237 in Participants With Psoriasis
A Phase 1, Double-Blind, Randomized, Placebo-Controlled, Multiple Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutaneous LY3361237 in Participants With Psoriasis
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Sofia, Bulgaria, 1606
- MC Comac Medical
-
-
-
-
-
Budapest, Hungary, 1027
- Budai Irgalmasrendi Korhaz
-
-
-
-
-
Lodz, Poland, 94048
- All Med - Lodz
-
Poznan, Poland, 61-113
- Ai Centrum Medyczne Sp. Z O.O. Sp.K.
-
Warszawa, Poland, 00-728
- WIP Warsaw IBD Point Profesor Kierkus
-
Warszawa, Poland, 01-868
- Pratia - Warsaw
-
-
-
-
-
Bratislava, Slovakia, 831
- Summit Clinical Research, s.r.o. - Bratislava
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Have chronic plaque psoriasis for at least 6 months
- Be willing and able to undergo skin biopsies
- Body mass index (BMI) within the range of 18 to 40 kilograms per meter squared (kg/m²)
- Female participants must agree to use birth control during the study
Exclusion Criteria:
- Have had certain types of infection within the last six months
- Have a clinically significant active infection, or recent acute active infection within the last 30 days
- Have other serious or unstable illnesses
- Have a history of organ or bone marrow transplant
- Have received any live vaccine within the last 4 weeks prior to screening
- Have received systemic nonbiologic psoriasis therapy within 4 weeks prior to study day 1
- Have received topical psoriasis treatment within 14 days prior to study day 1
- Have excessive skin exposure or use tanning booths for at least 4 weeks prior to study day 1
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Placebo Comparator: Placebo
Placebo administered SC.
|
Administered SC
|
|
Experimental: LY3361237
LY3361237 administered subcutaneously (SC).
|
Administered SC
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of Participants with One or More Treatment-Emergent Adverse Event(s) (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration
Time Frame: Baseline through Day 253
|
A summary of TEAEs, SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module
|
Baseline through Day 253
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Pharmacokinetics (PK): Minimum Serum Concentration (Cmin) of LY3361237 During the Dosing Interval
Time Frame: Day 1 predose through Day 253
|
PK: Cmin of LY3361237 During the Dosing Interval
|
Day 1 predose through Day 253
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 17291
- I9S-MC-BTAC (Other Identifier: Eli Lilly and Company)
- 2019-003187-40 (EudraCT Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.